Gene Solutions Secures Patent for Novel Mitochondrial Therapy Platform Targeting Neurological Diseases
Key Insights
Gene Solutions (search) has secured patent publication (WO 2025 168944 A1) for its breakthrough mitochondrial therapy platform targeting neurological diseases including Alzheimer's and Parkinson's disease (search).
The company has developed DNA-binding polyamides (search) (DBPAs) that exhibit greater than 90-fold selectivity for mutated DNA sequences over wild-type sequences in mitochondrial genes.
The patented platform covers novel therapeutic lead candidate compounds that target mitochondrial dysfunction by recognizing and downregulating transcription of defective genes.
Gene Solutions (search) announced the publication of its platform technology patent covering novel mitochondrial dysfunction therapeutics, marking a significant advancement in the treatment of neurological diseases including Alzheimer's, Parkinson's, and related disorders. The patent publication (WO 2025 168944 A1) and subsequent PCT filing solidifies the company's research and development leadership in advanced neurotherapeutics.
Revolutionary Approach to Mitochondrial Dysfunction
The patented technology addresses a fundamental challenge in neurological disease treatment by targeting mitochondrial dysfunction at its source. Mitochondria supply 90% of the energy needed by the body's cells and regulate various biological functions, including cell death. When mitochondrial dysfunction occurs, it can lead to the onset of neurodegenerative diseases by compromising energy production.
Mitochondria contain their own small genome (mtDNA (search)), which comprises genes that encode for proteins associated with adenosine triphosphate (ATP) production. Mitochondrial dysfunction occurs when one or more of these genes contains defects, specifically mutations called Single Nucleotide Polymorphisms (SNPs), resulting in reduced ATP production. Diseases related to mitochondrial dysfunction arise when these SNPs cause ATP production to fall below a critical threshold.
Novel DNA-Binding Polyamides Show Exceptional Selectivity
Gene Solutions (search) has developed a new generation of gene regulatory compounds known as DNA-binding polyamides (search) (DBPAs) that recognize mutated SNPs and downregulate transcription. The company's DBPAs demonstrate remarkable specificity, exhibiting greater than 90-fold selectivity for a desired SNP over wild-type sequences.
This exceptional selectivity has been demonstrated with the SNP associated with the COXIII (search) gene present in a range of mitochondrial diseases, including mitochondrial encephalomyopathy (search), lactic acidosis, and stroke-like episodes (MELAS (search)). The company has developed a combined biophysical and biochemical platform to assess the potency and selectivity of this new generation of DBPA candidates.
Strategic Patent Protection and Commercial Rights
The awarded patent claims cover both the novel technologies underpinning Gene Solutions (search)' platform for identification and development of mitochondrial dysfunction therapeutics, as well as a substantial range of novel therapeutic lead candidate compounds. Gene Solutions funded the discovery research project in collaboration with the University of Strathclyde's cross-functional chemistry, biology, and molecular diagnostic teams.
While the patent was applied for and awarded to the University of Strathclyde, Gene Solutions (search) retains exclusive commercialization rights to the patent and maintains the right to be assigned the patent if desired by the company or its partners.
Industry Impact and Future Prospects
"The publication of our platform and lead candidate library patent marks a significant milestone in our commitment to transforming the landscape of neurological disease research and treatment," said James Oury, Gene Solutions (search) board member. "This achievement protects our proprietary inventions and strengthens our position as a collaborator of choice for pharmaceutical and biotechnology partners worldwide."
Gene Solutions (search) operates as a biotechnology company specializing in therapeutic research for CNS diseases, with a focus on mitochondrial genomics and innovative biomarkers. The company collaborates globally to accelerate drug discovery and diagnostics for conditions such as Alzheimer's, Parkinson's, and Schizophrenia (search), with research expertise spanning the USA and UK.